Mucopolysaccharidosis (MPS) Treatment Market Report

Global Mucopolysaccharidosis (MPS) Treatment Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • POSTDATE：Mar 03, 2022
  • PAGES：179
  • REPORT CODE：GMM795463
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Mucopolysaccharidosis (MPS) Treatment market report explains the definition, types, applications, major countries, and major players of the Mucopolysaccharidosis (MPS) Treatment market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • Abeona Therapeutics

    • BioMarin Pharmaceutical

    • ArmaGen

    • Eloxx Pharmaceuticals

    • Sanofi

    • Esteve

    • REGENXBIO Inc

    • Shire (Takeda)

    • Sangamo Therapeutics

    • Inventiva

    • Ultragenyx Pharmaceutical

    By Type:

    • Stem Cell Therapies

    • Enzyme Replacement Therapies

    By End-User:

    • Hospitals

    • Clinics

    • Homecare

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global Mucopolysaccharidosis (MPS) Treatment Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 Mucopolysaccharidosis (MPS) Treatment Outlook to 2028- Original Forecasts

    • 2.2 Mucopolysaccharidosis (MPS) Treatment Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term Mucopolysaccharidosis (MPS) Treatment Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global Mucopolysaccharidosis (MPS) Treatment Market- Recent Developments

    • 6.1 Mucopolysaccharidosis (MPS) Treatment Market News and Developments

    • 6.2 Mucopolysaccharidosis (MPS) Treatment Market Deals Landscape

    7 Mucopolysaccharidosis (MPS) Treatment Raw Materials and Cost Structure Analysis

    • 7.1 Mucopolysaccharidosis (MPS) Treatment Key Raw Materials

    • 7.2 Mucopolysaccharidosis (MPS) Treatment Price Trend of Key Raw Materials

    • 7.3 Mucopolysaccharidosis (MPS) Treatment Key Suppliers of Raw Materials

    • 7.4 Mucopolysaccharidosis (MPS) Treatment Market Concentration Rate of Raw Materials

    • 7.5 Mucopolysaccharidosis (MPS) Treatment Cost Structure Analysis

      • 7.5.1 Mucopolysaccharidosis (MPS) Treatment Raw Materials Analysis

      • 7.5.2 Mucopolysaccharidosis (MPS) Treatment Labor Cost Analysis

      • 7.5.3 Mucopolysaccharidosis (MPS) Treatment Manufacturing Expenses Analysis

    8 Global Mucopolysaccharidosis (MPS) Treatment Import and Export Analysis (Top 10 Countries)

    • 8.1 Global Mucopolysaccharidosis (MPS) Treatment Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global Mucopolysaccharidosis (MPS) Treatment Export by Region (Top 10 Countries) (2017-2028)

    9 Global Mucopolysaccharidosis (MPS) Treatment Market Outlook by Types and Applications to 2022

    • 9.1 Global Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Stem Cell Therapies Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Enzyme Replacement Therapies Consumption and Growth Rate (2017-2022)

    • 9.2 Global Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospitals Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Clinics Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Homecare Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise Mucopolysaccharidosis (MPS) Treatment Market Analysis and Outlook till 2022

    • 10.1 Global Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

      • 10.2.2 Canada Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

      • 10.2.3 Mexico Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

      • 10.3.2 UK Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

      • 10.3.3 Spain Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

      • 10.3.4 Belgium Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

      • 10.3.5 France Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

      • 10.3.6 Italy Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

      • 10.3.7 Denmark Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

      • 10.3.8 Finland Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

      • 10.3.9 Norway Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

      • 10.3.10 Sweden Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

      • 10.3.11 Poland Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

      • 10.3.12 Russia Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

      • 10.3.13 Turkey Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

      • 10.4.2 Japan Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

      • 10.4.3 India Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

      • 10.4.4 South Korea Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

      • 10.4.5 Pakistan Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

      • 10.4.6 Bangladesh Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

      • 10.4.7 Indonesia Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

      • 10.4.8 Thailand Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

      • 10.4.9 Singapore Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

      • 10.4.10 Malaysia Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

      • 10.4.11 Philippines Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

      • 10.4.12 Vietnam Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

      • 10.5.2 Colombia Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

      • 10.5.3 Chile Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

      • 10.5.4 Argentina Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

      • 10.5.5 Venezuela Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

      • 10.5.6 Peru Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

      • 10.5.7 Puerto Rico Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

      • 10.5.8 Ecuador Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

      • 10.6.2 Kuwait Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

      • 10.6.3 Oman Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

      • 10.6.4 Qatar Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

      • 10.6.5 Saudi Arabia Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

      • 10.6.6 United Arab Emirates Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

      • 10.7.2 South Africa Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

      • 10.7.3 Egypt Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

      • 10.7.4 Algeria Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

      • 10.8.2 New Zealand Mucopolysaccharidosis (MPS) Treatment Consumption (2017-2022)

    11 Global Mucopolysaccharidosis (MPS) Treatment Competitive Analysis

    • 11.1 Abeona Therapeutics

      • 11.1.1 Abeona Therapeutics Company Details

      • 11.1.2 Abeona Therapeutics Mucopolysaccharidosis (MPS) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 Abeona Therapeutics Mucopolysaccharidosis (MPS) Treatment Main Business and Markets Served

      • 11.1.4 Abeona Therapeutics Mucopolysaccharidosis (MPS) Treatment Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 BioMarin Pharmaceutical

      • 11.2.1 BioMarin Pharmaceutical Company Details

      • 11.2.2 BioMarin Pharmaceutical Mucopolysaccharidosis (MPS) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 BioMarin Pharmaceutical Mucopolysaccharidosis (MPS) Treatment Main Business and Markets Served

      • 11.2.4 BioMarin Pharmaceutical Mucopolysaccharidosis (MPS) Treatment Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 ArmaGen

      • 11.3.1 ArmaGen Company Details

      • 11.3.2 ArmaGen Mucopolysaccharidosis (MPS) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 ArmaGen Mucopolysaccharidosis (MPS) Treatment Main Business and Markets Served

      • 11.3.4 ArmaGen Mucopolysaccharidosis (MPS) Treatment Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 Eloxx Pharmaceuticals

      • 11.4.1 Eloxx Pharmaceuticals Company Details

      • 11.4.2 Eloxx Pharmaceuticals Mucopolysaccharidosis (MPS) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 Eloxx Pharmaceuticals Mucopolysaccharidosis (MPS) Treatment Main Business and Markets Served

      • 11.4.4 Eloxx Pharmaceuticals Mucopolysaccharidosis (MPS) Treatment Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 Sanofi

      • 11.5.1 Sanofi Company Details

      • 11.5.2 Sanofi Mucopolysaccharidosis (MPS) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 Sanofi Mucopolysaccharidosis (MPS) Treatment Main Business and Markets Served

      • 11.5.4 Sanofi Mucopolysaccharidosis (MPS) Treatment Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    • 11.6 Esteve

      • 11.6.1 Esteve Company Details

      • 11.6.2 Esteve Mucopolysaccharidosis (MPS) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.6.3 Esteve Mucopolysaccharidosis (MPS) Treatment Main Business and Markets Served

      • 11.6.4 Esteve Mucopolysaccharidosis (MPS) Treatment Product Portfolio

      • 11.6.5 Recent Research and Development Strategies

    • 11.7 REGENXBIO Inc

      • 11.7.1 REGENXBIO Inc Company Details

      • 11.7.2 REGENXBIO Inc Mucopolysaccharidosis (MPS) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.7.3 REGENXBIO Inc Mucopolysaccharidosis (MPS) Treatment Main Business and Markets Served

      • 11.7.4 REGENXBIO Inc Mucopolysaccharidosis (MPS) Treatment Product Portfolio

      • 11.7.5 Recent Research and Development Strategies

    • 11.8 Shire (Takeda)

      • 11.8.1 Shire (Takeda) Company Details

      • 11.8.2 Shire (Takeda) Mucopolysaccharidosis (MPS) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.8.3 Shire (Takeda) Mucopolysaccharidosis (MPS) Treatment Main Business and Markets Served

      • 11.8.4 Shire (Takeda) Mucopolysaccharidosis (MPS) Treatment Product Portfolio

      • 11.8.5 Recent Research and Development Strategies

    • 11.9 Sangamo Therapeutics

      • 11.9.1 Sangamo Therapeutics Company Details

      • 11.9.2 Sangamo Therapeutics Mucopolysaccharidosis (MPS) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.9.3 Sangamo Therapeutics Mucopolysaccharidosis (MPS) Treatment Main Business and Markets Served

      • 11.9.4 Sangamo Therapeutics Mucopolysaccharidosis (MPS) Treatment Product Portfolio

      • 11.9.5 Recent Research and Development Strategies

    • 11.10 Inventiva

      • 11.10.1 Inventiva Company Details

      • 11.10.2 Inventiva Mucopolysaccharidosis (MPS) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.10.3 Inventiva Mucopolysaccharidosis (MPS) Treatment Main Business and Markets Served

      • 11.10.4 Inventiva Mucopolysaccharidosis (MPS) Treatment Product Portfolio

      • 11.10.5 Recent Research and Development Strategies

    • 11.11 Ultragenyx Pharmaceutical

      • 11.11.1 Ultragenyx Pharmaceutical Company Details

      • 11.11.2 Ultragenyx Pharmaceutical Mucopolysaccharidosis (MPS) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.11.3 Ultragenyx Pharmaceutical Mucopolysaccharidosis (MPS) Treatment Main Business and Markets Served

      • 11.11.4 Ultragenyx Pharmaceutical Mucopolysaccharidosis (MPS) Treatment Product Portfolio

      • 11.11.5 Recent Research and Development Strategies

    12 Global Mucopolysaccharidosis (MPS) Treatment Market Outlook by Types and Applications to 2028

    • 12.1 Global Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global Stem Cell Therapies Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global Enzyme Replacement Therapies Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Clinics Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.3 Global Homecare Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise Mucopolysaccharidosis (MPS) Treatment Market Analysis and Outlook to 2028

    • 13.1 Global Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

      • 13.2.2 Canada Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

      • 13.2.3 Mexico Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

      • 13.3.2 UK Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

      • 13.3.3 Spain Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

      • 13.3.4 Belgium Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

      • 13.3.5 France Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

      • 13.3.6 Italy Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

      • 13.3.7 Denmark Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

      • 13.3.8 Finland Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

      • 13.3.9 Norway Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

      • 13.3.10 Sweden Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

      • 13.3.11 Poland Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

      • 13.3.12 Russia Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

      • 13.3.13 Turkey Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

      • 13.4.2 Japan Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

      • 13.4.3 India Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

      • 13.4.4 South Korea Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

      • 13.4.8 Thailand Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

      • 13.4.9 Singapore Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

      • 13.4.11 Philippines Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

      • 13.5.2 Colombia Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

      • 13.5.3 Chile Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

      • 13.5.4 Argentina Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

      • 13.5.6 Peru Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

      • 13.6.3 Oman Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

      • 13.6.4 Qatar Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

      • 13.7.2 South Africa Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

      • 13.7.3 Egypt Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

      • 13.7.4 Algeria Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand Mucopolysaccharidosis (MPS) Treatment Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of Mucopolysaccharidosis (MPS) Treatment

    • Figure of Mucopolysaccharidosis (MPS) Treatment Picture

    • Table Global Mucopolysaccharidosis (MPS) Treatment Import by Region (Top 10 Countries) (2017-2028)

    • Table Global Mucopolysaccharidosis (MPS) Treatment Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global Stem Cell Therapies Consumption and Growth Rate (2017-2022)

    • Figure Global Enzyme Replacement Therapies Consumption and Growth Rate (2017-2022)

    • Figure Global Hospitals Consumption and Growth Rate (2017-2022)

    • Figure Global Clinics Consumption and Growth Rate (2017-2022)

    • Figure Global Homecare Consumption and Growth Rate (2017-2022)

    • Figure Global Mucopolysaccharidosis (MPS) Treatment Consumption by Country (2017-2022)

    • Table North America Mucopolysaccharidosis (MPS) Treatment Consumption by Country (2017-2022)

    • Figure United States Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Canada Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Mexico Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate (2017-2022)

    • Table Europe Mucopolysaccharidosis (MPS) Treatment Consumption by Country (2017-2022)

    • Figure Germany Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure UK Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Spain Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Belgium Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure France Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Italy Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Denmark Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Finland Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Norway Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Sweden Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Poland Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Russia Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Turkey Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate (2017-2022)

    • Table APAC Mucopolysaccharidosis (MPS) Treatment Consumption by Country (2017-2022)

    • Figure China Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Japan Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure India Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure South Korea Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Pakistan Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Indonesia Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Thailand Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Singapore Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Malaysia Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Philippines Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Vietnam Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate (2017-2022)

    • Table South America Mucopolysaccharidosis (MPS) Treatment Consumption by Country (2017-2022)

    • Figure Brazil Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Colombia Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Chile Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Argentina Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Venezuela Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Peru Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Ecuador Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate (2017-2022)

    • Table GCC Mucopolysaccharidosis (MPS) Treatment Consumption by Country (2017-2022)

    • Figure Bahrain Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Kuwait Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Oman Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Qatar Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate (2017-2022)

    • Table Africa Mucopolysaccharidosis (MPS) Treatment Consumption by Country (2017-2022)

    • Figure Nigeria Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure South Africa Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Egypt Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Algeria Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate (2017-2022)

    • Table Oceania Mucopolysaccharidosis (MPS) Treatment Consumption by Country (2017-2022)

    • Figure Australia Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure New Zealand Mucopolysaccharidosis (MPS) Treatment Consumption and Growth Rate (2017-2022)

    • Table Abeona Therapeutics Company Details

    • Table Abeona Therapeutics Mucopolysaccharidosis (MPS) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Abeona Therapeutics Mucopolysaccharidosis (MPS) Treatment Main Business and Markets Served

    • Table Abeona Therapeutics Mucopolysaccharidosis (MPS) Treatment Product Portfolio

    • Table BioMarin Pharmaceutical Company Details

    • Table BioMarin Pharmaceutical Mucopolysaccharidosis (MPS) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table BioMarin Pharmaceutical Mucopolysaccharidosis (MPS) Treatment Main Business and Markets Served

    • Table BioMarin Pharmaceutical Mucopolysaccharidosis (MPS) Treatment Product Portfolio

    • Table ArmaGen Company Details

    • Table ArmaGen Mucopolysaccharidosis (MPS) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table ArmaGen Mucopolysaccharidosis (MPS) Treatment Main Business and Markets Served

    • Table ArmaGen Mucopolysaccharidosis (MPS) Treatment Product Portfolio

    • Table Eloxx Pharmaceuticals Company Details

    • Table Eloxx Pharmaceuticals Mucopolysaccharidosis (MPS) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Eloxx Pharmaceuticals Mucopolysaccharidosis (MPS) Treatment Main Business and Markets Served

    • Table Eloxx Pharmaceuticals Mucopolysaccharidosis (MPS) Treatment Product Portfolio

    • Table Sanofi Company Details

    • Table Sanofi Mucopolysaccharidosis (MPS) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sanofi Mucopolysaccharidosis (MPS) Treatment Main Business and Markets Served

    • Table Sanofi Mucopolysaccharidosis (MPS) Treatment Product Portfolio

    • Table Esteve Company Details

    • Table Esteve Mucopolysaccharidosis (MPS) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Esteve Mucopolysaccharidosis (MPS) Treatment Main Business and Markets Served

    • Table Esteve Mucopolysaccharidosis (MPS) Treatment Product Portfolio

    • Table REGENXBIO Inc Company Details

    • Table REGENXBIO Inc Mucopolysaccharidosis (MPS) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table REGENXBIO Inc Mucopolysaccharidosis (MPS) Treatment Main Business and Markets Served

    • Table REGENXBIO Inc Mucopolysaccharidosis (MPS) Treatment Product Portfolio

    • Table Shire (Takeda) Company Details

    • Table Shire (Takeda) Mucopolysaccharidosis (MPS) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Shire (Takeda) Mucopolysaccharidosis (MPS) Treatment Main Business and Markets Served

    • Table Shire (Takeda) Mucopolysaccharidosis (MPS) Treatment Product Portfolio

    • Table Sangamo Therapeutics Company Details

    • Table Sangamo Therapeutics Mucopolysaccharidosis (MPS) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sangamo Therapeutics Mucopolysaccharidosis (MPS) Treatment Main Business and Markets Served

    • Table Sangamo Therapeutics Mucopolysaccharidosis (MPS) Treatment Product Portfolio

    • Table Inventiva Company Details

    • Table Inventiva Mucopolysaccharidosis (MPS) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Inventiva Mucopolysaccharidosis (MPS) Treatment Main Business and Markets Served

    • Table Inventiva Mucopolysaccharidosis (MPS) Treatment Product Portfolio

    • Table Ultragenyx Pharmaceutical Company Details

    • Table Ultragenyx Pharmaceutical Mucopolysaccharidosis (MPS) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Ultragenyx Pharmaceutical Mucopolysaccharidosis (MPS) Treatment Main Business and Markets Served

    • Table Ultragenyx Pharmaceutical Mucopolysaccharidosis (MPS) Treatment Product Portfolio

    • Figure Global Stem Cell Therapies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Enzyme Replacement Therapies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Clinics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Homecare Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Mucopolysaccharidosis (MPS) Treatment Consumption Forecast by Country (2022-2028)

    • Table North America Mucopolysaccharidosis (MPS) Treatment Consumption Forecast by Country (2022-2028)

    • Figure United States Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Mucopolysaccharidosis (MPS) Treatment Consumption Forecast by Country (2022-2028)

    • Figure Germany Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure France Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC Mucopolysaccharidosis (MPS) Treatment Consumption Forecast by Country (2022-2028)

    • Figure China Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table South America Mucopolysaccharidosis (MPS) Treatment Consumption Forecast by Country (2022-2028)

    • Figure Brazil Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC Mucopolysaccharidosis (MPS) Treatment Consumption Forecast by Country (2022-2028)

    • Figure Bahrain Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa Mucopolysaccharidosis (MPS) Treatment Consumption Forecast by Country (2022-2028)

    • Figure Nigeria Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania Mucopolysaccharidosis (MPS) Treatment Consumption Forecast by Country (2022-2028)

    • Figure Australia Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand Mucopolysaccharidosis (MPS) Treatment Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US